SEC Filing Summary: Corcept Therapeutics Inc. (CORT)
Business Context and Reporting Period
This Form 8-K, dated June 10, 2025, reports on the results of Corcept Therapeutics Incorporated's 2025 Annual Meeting of Stockholders. The meeting was held to vote on the election of directors, the ratification of the independent auditor, and an advisory vote on executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Out of 106,044,683 shares entitled to vote, 92,327,139 shares were voted at the Annual Meeting. The outcomes for the three proposals were as follows:
- Proposal 1 (Election of Directors): All nine nominees were elected. Notable voting patterns included significant "Withheld" votes for David L. Mahoney (14,718,722) and Kimberly Park (6,852,716), while other directors received fewer than 2.5 million withheld votes.
- Proposal 2 (Ratification of Auditor): The appointment of Ernst & Young LLP was ratified with 90,463,359 votes "For" and 1,488,132 votes "Against."
- Proposal 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 72,914,293 votes "For" and 4,195,859 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the reasons behind the high number of "Withheld" votes for directors David L. Mahoney and Kimberly Park compared to other nominees.
- Confirm the total number of shares outstanding and the percentage of shares represented by the 14.9 million broker non-votes.
- Review the full proxy statement for details on the specific executive compensation packages approved in Proposal 3.